I
Innovo Therapeutics
Innovo Therapeutics is committed to discovering and developing the next generation of protein degraders in areas of high unmet medical need
About Innovo Therapeutics
Innovo Therapeutics, Inc. is a biopharmaceutical company established on January 14, 2020, and headquartered in San Diego, California. The company is led by founder and CEO, Dr. Weilin Xie, a seasoned scientist with deep expertise in the field of protein degradation. Dr. Xie's background includes a significant tenure at Celgene Corporation, where he was a Principal Senior Scientist, directed the fibrosis research unit, and notably co-initiated the firm's protein homeostasis drug discovery program focused on E2 and E3 ubiquitin ligases. This experience in identifying the mechanisms of blockbuster IMiD drugs provides a strong foundation for Innovo's strategic direction.
The company operates in the oncology market, concentrating on the discovery and development of protein degraders for areas with high unmet medical needs. Its business model centers on leveraging a high-throughput chemistry platform to build a differentiated pipeline and advance its programs through corporate and academic alliances. The operational strategy is a hybrid model, combining the drug discovery experience of its US team with pre-clinical resources and infrastructure in China to optimize efficiency and productivity.
Innovo's core technology is its targeted protein degradation platform, referred to as TriNovo. This platform utilizes a 'molecular glue' approach to drug development. Molecular glues are small molecules that induce a connection between a target protein and an E3 ubiquitin ligase, a component of the cell's natural protein disposal system. This induced proximity marks the disease-causing protein for destruction by the proteasome. This method allows the company to pursue targets previously considered 'undruggable' by traditional inhibitors. One of the company's lead candidates developed from this platform is INNO-220, an orally active and highly selective CK1α molecular glue degrader. INNO-220 has shown potent anti-tumor activity against B-cell lymphomas, including in models resistant to existing treatments, by promoting the degradation of casein kinase 1 alpha (CK1α). The platform has also produced INNO-235, a dual-target degrader for GSPT1 and CK1α, which shows promise for treating MYC-driven malignancies like Burkitt lymphoma.
In addition to its internal discovery engine, Innovo has secured the worldwide exclusive rights to Rosmantuzumab, a humanized monoclonal antibody targeting R-spondin 3 (RSPO3). This Phase 2 clinical program adds a later-stage asset to its pipeline. The company actively seeks pharmaceutical partnerships to advance its pipeline programs and drive value from its differentiated discovery approach.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SEED✓Equity / VC | Dec 2023 | $14M | $55M | CICC · Ming Bioventures · Huajin Capital · Qiandao Fund | ↗ |
| ANGEL✓Equity / VC | May 2022 | $0 | — | Undisclosed | — |
Growth signals
Latest recorded traffic for Innovo Therapeutics is 130 monthly website visits, up 8.3% over the last three months. Innovo Therapeutics's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Innovo Therapeutics in the San Diego ecosystem
The Innovo Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed5 investors entered at this stage
Huajin Capital
CICC
Ming Bioventures- QFQiandao Fund
- HFHainan Longmen Fund
Other known investors2 additional known investors
Medical University of South Carolina- HVHMC Ventures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Innovo Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Innovo Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








